Table 1.

Patient demographics and baseline characteristics for the ATTRACTION-2 HPD analysis population

Characteristic	Placebo (n=115)	Nivolumab 3 mg/kg (n=243)
Age, years, median (range)	61 (26–83)	63 (20–83)
Female, n (%)	28 (24.4)	60 (24.7)
Race, n (%)
Asian	115 (100.0)	242 (99.6)
Native Hawaiian/other Pacific Islander	0	1 (0.4)
ECOG PS, n (%)
0	28 (24.4)	64 (26.3)
1	71 (61.7)	161 (66.3)
Baseline tumor size, cm
Mean (SD)	7.9 (5.1)	8.2 (5.8)
Median (range)	6.6 (1.3–25.3)	6.7 (1–31.3)

ECOG PS, Eastern Cooperative Oncology Group performance status; HPD, hyperprogressive disease.